; IHD, ischemic heart disease. Discussion Since the initial reports linking ADT to cardiac events emerged at the beginning of the 21st century, we witnessed a surge of literature evaluating the cardiovascular risk in patients treated with ADT
Search Results
Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian
Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund
overlapping risk factors and cardiotoxicities associated with cancer treatments may increase cardiovascular risk in this population. There have been few large studies that have assessed the burden of specific CVDs in breast cancer survivors, with most studies
Shing Fung Lee, Pui Lam Yip, Balamurugan A. Vellayappan, Cheng Ean Chee, Lea Choung Wong, Eric Yuk-Fai Wan, Esther Wai-Yin Chan, Chak-Fei Lee, Francis Ann-Shing Lee, and Miguel Angel Luque-Fernandez
/oxaliplatin), and FOLFOX (leucovorin/5-FU/oxaliplatin). Other treatment data included the number of cycles and any dose reduction. Preexisting Cardiovascular Risk Factors, Comorbidities, and Other Variables We retrieved data on the preexisting cardiovascular
NCCN Announces Collaboration With Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients With Prostate Cancer The NCCN Oncology Research Program ( ORP ) announced a collaboration with
Andrew T. Kuykendall and Rami Komrokji
corresponding risk category being assigned. 2 – 4 Additional risk factors have been proposed but not universally incorporated into risk-stratification models, including cardiovascular risk factors, leukocytosis, and, perhaps most controversially, platelet count
Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group
– 3115 . 9. Haugnes HS Wethal T Aass N . Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study . J Clin Oncol 2010 ; 28 : 4649 – 4657 . 10. Huddart RA Norman A Shahidi M
Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
subsequent analysis of 891 patients with ET, age >60 years, history of thrombosis, cardiovascular risk factors, and presence of JAK2 V617F mutation retained their prognostic significance regarding thrombosis risk in multivariable analysis. 17 Thus, a
Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron
coronary artery disease, cardiomyopathy, congestive heart failure, moderate to severe valvular heart disease, or ischemic stroke. Data Acquisition Patient demographics, comorbidities (including history of cancer, cardiovascular risk factors
Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron
, cardiomyopathy, congestive heart failure, moderate to severe valvular heart disease, or ischemic stroke. Data Acquisition Patient demographics, comorbidities (including history of cancer, cardiovascular risk factors, preexisting CVD, chronic kidney disease [CKD
Darren R. Feldman, Wendy L. Schaffer, and Richard M. Steingart
association, known as the direct and indirect vascular damage hypotheses, 4 is summarized and recommendations for how to approach cisplatin-treated GCT survivors, given their potential cardiovascular risks, are provided. Additional late toxicities occurring
